Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

pembrolizumab 2lenvatinib 2aldesleukin 2Paclitaxel 2Cisplatin 2Carboplatin 2Adoptive Transfer 2trastuzumab deruxtecan 1tivozanib 1liposomal doxorubicin 1fludarabine 1dostarlimab 1belzutifan 1atezolizumab 1Vaccines, Synthetic 1Therapeutic Touch 1Taxes 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Radiation 1Practice Guidelines as Topic 1Platinum 1Papillomavirus Vaccines 1Nivolumab 1Nelfinavir 1Imiquimod 1Hysterectomy 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Vulvar Neoplasms × tivozanib × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡